查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲癫痫市场预测至 2030 年 - 区域分析 - 按类型、给药途径、治疗类型、年龄层和配销通路
市场调查报告书
商品编码
1592590

欧洲癫痫市场预测至 2030 年 - 区域分析 - 按类型、给药途径、治疗类型、年龄层和配销通路

Europe Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 订单完成后即时交付

价格

2022年欧洲癫痫市场价值为19.4058亿美元，预计到2030年将达到26.2605亿美元；预计2022年至2030年复合年增长率为3.9%。

增加对癫痫疗法开发的投资推动欧洲癫痫市场

随着技术的快速发展和创新，医疗保健产业正在发生变革，提高了医疗保健服务和照护品质。癫痫市场的特征是存在多家小型和大型公司和组织，实施各种成长策略。资金的可用性使公司和组织能够提高生产水平，拓展新市场，投资新的/改进的技术，并为研发分配更多资源。以下提到了癫痫市场上一些对市场进步有贡献的着名投资。

2023 年 3 月，瑞典政府决定委託瑞典创新机构 Vinnova 拨款 770 万美元（8,000 万瑞典克朗）建立国家创新集群，用于细胞疗法和药物的商业化、技能开发和生产能力建设。 ，例如基因疗法。

2022 年 11 月，英国阿斯顿大学的科学家致力于开发预防儿童癫痫发作的新药物治疗项目，获得了 240 万美元（200 万英镑）的资助，以发现大脑中的疾病机制和预防癫痫的方法。这个为期三年的计画由医学研究委员会资助，由阿斯顿大学健康与生命科学学院的研究人员与布里斯託大学和 Jazz Pharmaceuticals 共同领导。

2022 年 7 月，Cerebral Therapeutics 在 C 轮融资中获得了 4,000 万美元，为其植入式输注癫痫治疗做好第三阶段开发的准备。此轮融资由 Lynx1 Capital Management 领投，其他投资者包括 RA Capital Management 和 Perceptive Advisors。 Cerebral Therapeutics 旨在将指定水平的丙戊酸输送至中枢神经系统，而不引起体重增加，这一点在口服製剂研究的受试者中得到了证实。

2021 年 11 月，位于印第安纳州的新创公司 Neurava 获得了超过 65 万美元的种子资金，由 Elevate Ventures 领投，普渡大学 Foundry、UCB Biopharma、First Leaf Capital、iO Life Ventures 和天使投资者跟随。该公司正在开发一款穿戴式设备，用于监测和提醒用户癫痫引起的猝死风险即将来临。

2021 年 6 月，生物治疗公司 Neurona Therapeutics Inc. 成功完成了 4,150 万美元融资，以推进该公司针对各种适应症的全资现成细胞疗法产品线，包括 NRTX-1001（1 期/ 2a 临床研究） ，一种用于治疗慢性局部癫痫的抑制性神经元细胞疗法。

因此，增加对先进治疗方法开发的投资推动了癫痫市场的成长。

欧洲癫痫市场概况

欧洲癫痫市场分为德国、英国、法国、义大利、西班牙和欧洲其他地区。该地区在癫痫市场占有重要的市场份额。由于老年人口显着增长、监管机构批准新药、政府增加资金以改善和开发有效的癫痫药物和治疗方法等因素，预计欧洲癫痫市场在预测期内将出现显着增长。

欧洲癫痫市场收入及 2030 年预测（百万美元）

欧洲癫痫市场细分

欧洲癫痫市场按类型、给药途径、治疗类型、年龄层、配销通路和国家分类。

依类型，欧洲癫痫市场分为进行性肌阵挛癫痫、反射性癫痫、全身性癫痫等。 2022 年，全身性癫痫细分市场占最大市场。

就给药途径而言，欧洲癫痫市场分为口服、肠胃外和其他。 2022 年，口腔细分市场占据最大的市场份额。

依治疗类型，欧洲癫痫市场分为第一代药物、第二代药物和第三代药物。 2022年，第三代药物细分市场占据最大市场份额。

根据年龄组，欧洲癫痫市场分为成人和儿童。 2022 年，成人细分市场将占据更大的市场份额。

从配销通路来看，欧洲癫痫市场分为医院药局、零售药局等。 2022年，医院药局领域占据最大的市场份额。

依国家划分，欧洲癫痫市场分为英国、德国、法国、义大利、西班牙和欧洲其他地区。 2022 年，英国在欧洲癫痫市场份额中占据主导地位。

Abbott Laboratories、Pfizer Inc、Eisai Co Ltd、UCB SA、CombiGene AB、LivaNova Plc、Novartis AG、Medtronic Plc、GSK Plc 和 H. Lundbeck AS 是欧洲癫痫市场上的一些领先公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 主要见解
  • 市场吸引力

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：欧洲癫痫治疗方法的管道研究

  • 癫痫治疗方法的管道研究
    • 细胞和基因治疗方法
    • 胶囊细胞生物递送（ECB）系统
    • 癫痫基因治疗临床概述
      • 癫痫临床研究采用基因疗法
      • 癫痫病毒载体的管道研究
      • 癫痫非病毒载体的管道研究
      • 腺相关病毒 (AAV) 介导的神经调节胜肽 - 概述
      • 基因治疗方法的神经营养因子
      • 人类癫痫表型的钾通道
      • 酶诱导抗癫痫药

第 5 章：欧洲癫痫市场 - 主要市场动态

  • 市场驱动因素
    • 癫痫盛行率上升
    • 增加癫痫疗法开发的投资
  • 市场限制
    • 产品召回
  • 市场机会
    • 组织所进行的意识计画激增
  • 未来趋势
    • 基因疗法作为有前景的治疗方法
  • 驱动因素和限制的影响：

第 6 章：癫痫市场 - 欧洲分析

  • 欧洲：癫痫市场

第 7 章：欧洲癫痫市场分析 - 按类型

  • 概述
  • 进行性肌阵挛癫痫
  • 反射性癫痫
  • 全身性癫痫
  • 其他

第 8 章：欧洲癫痫市场分析 - 按给药途径

  • 概述
  • 口服
  • 注射用
  • 其他的

第 9 章：欧洲癫痫市场分析 - 按治疗类型

  • 概述
  • 第一代药物
  • 第二代药物
  • 第三代药物

第 10 章：欧洲癫痫市场分析 - 按年龄组

  • 概述
  • 成人
  • 孩子们

第 11 章：欧洲癫痫市场分析 - 按配销通路

  • 概述
  • 医院药房
  • 零售药局
  • 其他的

第 12 章：欧洲癫痫市场 - 国家分析

  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区

第 13 章：产业格局

  • 概述
  • 癫痫市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 14 章：公司简介

  • Abbott Laboratories
  • Pfizer Inc
  • Eisai Co Ltd
  • UCB SA
  • CombiGene AB
  • LivaNova Plc
  • Novartis AG
  • Medtronic Plc
  • GSK Plc
  • H. Lundbeck AS

第 15 章：附录

Product Code: BMIRE00030744

The Europe epilepsy market was valued at US$ 1,940.58 million in 2022 and is expected to reach US$ 2,626.05 million by 2030; it is estimated to register a CAGR of 3.9% from 2022 to 2030.

Increasing Investments in Development of Epilepsy Therapies Drive Europe Epilepsy Market

The healthcare sector is transforming with rapid technological developments and innovation, enhancing healthcare services and quality of care. The epilepsy market is characterized by the presence of several small and large companies and organizations implementing various growth strategies. The availability of funding enables companies and organizations to boost production levels, expand into new markets, invest in new/improved technologies, and allocate more resources to R&D. A few of the notable investments in the epilepsy market, contributing to the market progress, have been mentioned below.

In March 2023, the Swedish government decided to commission Vinnova, Sweden's innovation agency, a total of US$ 7.7 million (80 million SEK) to establish a national innovation cluster for commercialization, skills development, and production capacity build-up for cell therapies and other advanced treatments such as gene therapy.

In November 2022, Scientists at Aston University in the UK, working on a project to develop new drug treatments to prevent the beginning of childhood epilepsy, were awarded US$ 2.4 million (£2 million) to discover the disease mechanism in the brain and the ways of epilepsy prevention. This three-year project funded by the Medical Research Council is a collaboration led by researchers in the College of Health and Life Sciences at Aston University, combined with Bristol University and Jazz Pharmaceuticals.

In July 2022, Cerebral Therapeutics secured US$ 40 million in the Series C round funding to get its implanted infusion epilepsy treatment ready for phase 3 development. The funding round was led by Lynx1 Capital Management among other investors, including RA Capital Management and Perceptive Advisors. Cerebral Therapeutics intends to deliver the specified levels of valproate to the central nervous system without causing weight gain, which was witnessed in subjects of oral formulation studies.

In November 2021, Neurava, a startup located in Indiana, received over US$ 0.65 million in seed funding led by Elevate Ventures with participation from Purdue Foundry, UCB Biopharma, First Leaf Capital, iO Life Ventures, and angel investors. The company is working on the development of a wearable device to monitor and alert users about the approaching risk of sudden, unexpected death caused by epilepsy.

In June 2021, Neurona Therapeutics Inc., a biotherapeutics company, successfully completed a US$ 41.5 million financing to advance the company's pipeline of wholly owned, off-the-shelf cell therapies for various indications, including NRTX-1001 (a Phase 1/2a clinical study), an inhibitory neuronal cell therapy for the treatment of chronic focal epilepsy.

Therefore, increasing investments in the development of advanced treatments propels the growth of the epilepsy market.

Europe Epilepsy Market Overview

The European epilepsy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the epilepsy market. The European epilepsy market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, approvals of new drugs by regulatory authorities, increase in funding by governments to improve and develop effective drugs and treatments for seizures in the region.

Europe Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

Europe Epilepsy Market Segmentation

The Europe epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the Europe epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the Europe epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the Europe epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the Europe epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the Europe epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the Europe epilepsy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK dominated the Europe epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Europe epilepsy market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Pipeline Studies for Epilepsy Therapy Approaches

  • 4.1 Pipeline Studies for Epilepsy Therapy Approaches
    • 4.1.1 Cell and Gene Therapy Approaches
    • 4.1.2 Encapsulated cell bio delivery (ECB) system
    • 4.1.3 Gene Therapy for Epilepsy Clinical Overview
      • 4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
        • 4.1.3.1.1 Gene Supplementation - Overview
        • 4.1.3.1.2 Gene Modulation - Overview
        • 4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
        • 4.1.3.1.4 Neuropeptides - Overview
        • 4.1.3.1.5 Engineered Channels - Overview
        • 4.1.3.1.6 Endogenous Channels - Overview
      • 4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
      • 4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
        • 4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
        • 4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
      • 4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
      • 4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
      • 4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
      • 4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. Europe Epilepsy Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Epilepsy
    • 5.1.2 Increasing Investments in Development of Epilepsy Therapies
  • 5.2 Market Restraints
    • 5.2.1 Recall of Products
  • 5.3 Market Opportunities
    • 5.3.1 Surge in Awareness Programs Conducted by Organizations
  • 5.4 Future Trends
    • 5.4.1 Gene Therapy as Promising Treatment Approach
  • 5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - Europe Analysis

  • 6.1 Europe: Epilepsy Market

7. Europe Epilepsy Market Analysis - by Type

  • 7.1 Overview
  • 7.2 Progressive Myoclonic Epilepsy
    • 7.2.1 Overview
    • 7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Reflex Epilepsy
    • 7.3.1 Overview
    • 7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Generalized Epilepsy
    • 7.4.1 Overview
    • 7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Other
    • 7.5.1 Overview
    • 7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Epilepsy Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Epilepsy Market Analysis - by Treatment Type

  • 9.1 Overview
  • 9.2 First Generation Drugs
    • 9.2.1 Overview
    • 9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Second Generation Drugs
    • 9.3.1 Overview
    • 9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Third Generation Drugs
    • 9.4.1 Overview
    • 9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Epilepsy Market Analysis - by Age Group

  • 10.1 Overview
  • 10.2 Adult
    • 10.2.1 Overview
    • 10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Children
    • 10.3.1 Overview
    • 10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Epilepsy Market Analysis - by Distribution Channel

  • 11.1 Overview
  • 11.2 Hospital Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.3 Retail Pharmacies
    • 11.3.1 Overview
    • 11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.4 Others
    • 11.4.1 Overview
    • 11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. Europe Epilepsy Market - Country Analysis

  • 12.1 Europe: Epilepsy Market Overview
    • 12.1.1 Europe: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
      • 12.1.1.1 United Kingdom: Epilepsy Market Overview
      • 12.1.1.2 United Kingdom: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.2.1 United Kingdom: Epilepsy Market Breakdown, by Type
        • 12.1.1.2.2 United Kingdom: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.2.3 United Kingdom: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.2.4 United Kingdom: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.2.5 United Kingdom: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.3 Germany: Epilepsy Market Overview
      • 12.1.1.4 Germany: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.4.1 Germany: Epilepsy Market Breakdown, by Type
        • 12.1.1.4.2 Germany: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.4.3 Germany: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.4.4 Germany: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.4.5 Germany: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.5 France: Epilepsy Market Overview
      • 12.1.1.6 France: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.6.1 France: Epilepsy Market Breakdown, by Type
        • 12.1.1.6.2 France: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.6.3 France: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.6.4 France: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.6.5 France: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.7 Spain: Epilepsy Market Overview
      • 12.1.1.8 Spain: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.8.1 Spain: Epilepsy Market Breakdown, by Type
        • 12.1.1.8.2 Spain: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.8.3 Spain: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.8.4 Spain: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.8.5 Spain: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.9 Italy: Epilepsy Market Overview
      • 12.1.1.10 Italy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.10.1 Italy: Epilepsy Market Breakdown, by Type
        • 12.1.1.10.2 Italy: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.10.3 Italy: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.10.4 Italy: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.10.5 Italy: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.11 Rest of Europe: Epilepsy Market Overview
      • 12.1.1.12 Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.12.1 Rest of Europe: Epilepsy Market Breakdown, by Type
        • 12.1.1.12.2 Rest of Europe: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.12.3 Rest of Europe: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.12.4 Rest of Europe: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.12.5 Rest of Europe: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Epilepsy Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Abbott Laboratories
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Eisai Co Ltd
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 UCB SA
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 CombiGene AB
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 LivaNova Plc
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Novartis AG
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 Medtronic Plc
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 GSK Plc
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 H. Lundbeck AS
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners

List Of Tables

  • Table 1. Europe Epilepsy Market Segmentation
  • Table 2. Cell Therapy Approach - An Overview
  • Table 3. Gene Therapy Approach - An Overview
  • Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
  • Table 5. Preclinically Tested Genetic Therapies for Epilepsy
  • Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
  • Table 7. Viral Vectors Comparison with respect to Various Parameters
  • Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
  • Table 9. Enzyme-Inducing Antiepileptic Drugs
  • Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
  • Table 11. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 12. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 13. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 14. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 15. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 16. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 17. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 18. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 19. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 20. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 21. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 22. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 23. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 24. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 25. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 26. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 27. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 28. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 29. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 32. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 33. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 34. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 35. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 36. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 37. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 38. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 39. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 40. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 41. Recent Organic Growth Strategies in Epilepsy Market
  • Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market

List Of Figures

  • Figure 1. Europe Epilepsy Market Segmentation, by Country
  • Figure 2. Epilepsy Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
  • Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
  • Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
  • Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
  • Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
  • Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Europe: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Europe: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 32. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Growth Strategies in Epilepsy Market